Evidence map›Paper›PMID 41046319›Full record

ArticleLa Radiologia medica2026

CCM-ITALUNG2 pilot on lung cancer screening in Italy: recruitment, integration with smoking cessation and baseline results.

Giuseppe Gorini, Donella Puliti, Giulia Picozzi, Jasmine Giovannoli, Giulia Veronesi, Francesco Pistelli, Carlo Senore, Carlo Tessa, Edoardo Cavigli, Simonetta Bisanzi and 10 more

Erratum issuedAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Giuseppe GoriniInstitute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Donella PulitiInstitute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Giulia PicozziInstitute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy. g.picozzi@ispro.toscana.it.
Jasmine GiovannoliInstitute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Giulia VeronesiIRCCS San Raffaele Scientific Institute, Milan, Italy.
Francesco PistelliPisa University Hospital, Pisa, Italy.
Carlo SenoreEpidemiology and Screening Unit (CPO Piemonte), University Hospital "Città Della Salute E Della Scienza Di Torino", Turin, Italy.
Carlo TessaItaly Apuano Hospital, North-Western Tuscany Local Health Unit, Massa Carrara, Italy.
Edoardo CavigliCareggi Hospital, University of Florence, Florence, Italy.
Simonetta BisanziInstitute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Elisa DieciIRCCS San Raffaele Scientific Institute, Milan, Italy.
Piergiorgio MurianaIRCCS San Raffaele Scientific Institute, Milan, Italy.
Annalisa DeliperiPisa University Hospital, Pisa, Italy.
Emanuela RomanoEpidemiology and Screening Unit (CPO Piemonte), University Hospital "Città Della Salute E Della Scienza Di Torino", Turin, Italy.
Cristiano PiccinelliEpidemiology and Screening Unit (CPO Piemonte), University Hospital "Città Della Salute E Della Scienza Di Torino", Turin, Italy.
Paola VivaniItaly Apuano Hospital, North-Western Tuscany Local Health Unit, Massa Carrara, Italy.
Eugenio PaciLega Italiana Lotta Contro I Tumori (LILT), Florence, Italy.
Laura CarrozziPisa University Hospital, Pisa, Italy.
Mario MascalchiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence Florence University, Florence, Italy.
CCM-ITALUNG2 Pilot Working Group

Funding

Ministero della Salute 314/2019Regione Toscana 213/2020
6 · The paper itself

Abstract

backgroundThe CCM-ITALUNG2 pilot was implemented to evaluate the feasibility of an organized lung cancer (LC) screening programme in five Italian centres.

methodsThe screening pathway included invitation, recruitment, referral to Smoking Cessation Services (SCSs), and use of the Lung-RADS score for low-dose CT reading. Dedicated screening operators followed up participants from recruitment through the clinical follow-up established by multidisciplinary teams. Eligibility criteria included age 55-75 years, ever-smokers with ≥ 25 pack-years; quit within the past 10 years. Baseline round results are presented.

resultsFrom November 2022 to May 2024, 1,144 of the 1,971 invited individuals (58.0%) were recruited following different strategies including in-person invitation by general practitioners (GPs; 356 subjects, 31.9%) or other healthcare personnel (18.1%), self-presentation (36.3%), and phone invitation using GPs' patient lists (13.7%). Among current smokers, 38.5% accepted referral to SCSs. Eighteen subjects (77.8% in stage I-II) were diagnosed with LC (prevalent LC rate 1.57%). The mean time to surgery was 147 days (standard deviation 73); the false-positive rate was 1.38% (15/1,085).

conclusionsBy utilizing different organizational models, the pilot was tailored to the specific characteristics of each centre. Phone invitations from GPs' patient lists, in-person invitations by GPs and other healthcare personnel, and self-presentation might enhance equity of access in comparison with self-referral only. Dedicated screening operators, the use of the Lung-RADS scoring system, and a structured clinical follow-up supported participants throughout the screening pathway. Delivering brief advice for smoking cessation during recruitment and offering SCS referral were feasible within the screening pathway.

Indexed as

Early Detection of CancerLung NeoplasmsSmoking CessationTomography, X-Ray ComputedAgedFeasibility StudiesFemaleHumansItalyMaleMass ScreeningMiddle AgedPatient SelectionPilot ProjectsReferral and ConsultationIncidental findingsLow-dose CTLung cancer screeningLung nodulePrimary preventionSecondary preventionSmoking cessation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.